Jade Biosciences, Inc. Expense Breakdown
No Expense Breakdown for JBIO on this site yet.
- 2026-06-30: Jade101 $14.98M; Jade-003 $10.11M; Jade201 $6.10M.
- 2025-06-30: Jade101 $7.25M; Jade-003 $926.00K; Jade201 $8.36M.
Source checked: the stored Expense Breakdown page for JBIO.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Jade101 | Jade-003 | Jade201 |
|---|---|---|---|
| 2026-06-30 | $14.98M | $10.11M | $6.10M |
| 2025-06-30 | $7.25M | $926.00K | $8.36M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |